If approved, momelotinib will slide into GSK portfolio alongside Blenrep (belantamab mafodotin), its BCMA-targeting antibody-drug conjugate, which was approved in 2020 as a therapy for multiple ...
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback